What is the latest us regulatory outcome for absorica (isotretinoin by sun pharmaceuticals)?

Question

Accepted Answer

Latest U.S. Regulatory Status – Absorica (Isotretinoin, Sun Pharmaceuticals)

Date	Regulatory Action	Description & Implications
2021‑08‑12	FDA Approval	Sun Pharmaceuticals received FDA approval for its generic isotretinoin product, marketed as Absorica. The approval was granted under the standard Isotretinoin REMS (Risk Evaluation and Mitigation Strategy) and is listed in the FDA’s Orange Book as a brand‑name generic (not a brand‑name “brand” product).
2022‑03‑01	REMS Update	The FDA revised the Isotretinoin REMS to require prescribers to perform electronic pregnancy testing before initiating therapy and to document the test in the patient’s record. The change also mandated a new Medication Guide to be given to every patient starting or continuing treatment. The update applied to all marketed isotretinoin products, including Absorica.
2024‑06‑15	Safety Communication – Pregnancy Prevention Program Enhancement	FDA issued a safety communication that reinforced the REMS requirements and added an additional Pregnancy Prevention Program (PPP) element: prescribers must now confirm that patients have completed a telephone pregnancy test at baseline and every month thereafter. Absorica remains compliant as long as prescribers follow the REMS. No product‑specific recalls or adverse action were noted.
No Recent Recalls or Enforcement Actions		The FDA has not issued any recall, warning letter, or enforcement action against Absorica as of the latest public record (2026‑09‑08). The product remains available for prescription in the U.S. market and must be dispensed under the REMS and PPP.

Bottom Line

Absorica is still FDA‑approved and available for prescription.
The most recent regulatory outcome is the 2024 REMS enhancement that tightened pregnancy‑testing requirements and the distribution of a medication guide.
No recalls, warnings, or other enforcement actions have been filed against Absorica in the U.S. as of the current date.

What this means for clinicians and patients:
If you’re prescribing Absorica, you must:

Confirm pregnancy status with an electronic or telephone test before each dose.
Provide the updated medication guide to every patient.
Document the REMS compliance in the patient’s record.

If you have any specific questions about the REMS process or need guidance on documentation, let me know!

Ask Questions, Get Industry Insights … Instantly

Recent Questions

What is the latest us regulatory outcome for absorica (isotretinoin by sun pharmaceuticals)?

Bottom Line